The EMT participates in tumor progression by increasing cancer cell motility, migration, invasion, and adhesion and is characterized by upregulation of mesenchymal proteins, such as vimentin, fibronectin, and N-cadherin, and downregulation of epithelial markers, such as E-cadherin [12–14]. The gene discussed is CDH1; the disease is cancer.